

CHAPTER ONE: INTRODUCTION	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	2
INTENDED AUDIENCE.....	2
ANALYST CREDENTIALS.....	3
METHODOLOGY AND INFORMATION SOURCES.....	3
RELATED BCC REPORTS	4
BCC ONLINE SERVICES.....	4
DISCLAIMER	5
 CHAPTER TWO: SUMMARY.....	 6
<i>SUMMARY TABLE GLOBAL BIOBANKING REVENUES FORECAST BY SEGMENT, THROUGH 2015 (\$ MILLIONS)</i>	 6
<i>SUMMARY FIGURE GLOBAL BIOBANKING REVENUES FORECAST BY SEGMENT, 2009-2015 (\$ MILLIONS)</i>	 7
SUMMARY (CONTINUED)	8
 CHAPTER THREE: OVERVIEW	 9
CURRENT STATE OF THE INDUSTRY.....	9
THE PROCESS OF BIOBANKING	10
HISTORICAL CONTEXT.....	11
SCIENTIFIC AND COMMERCIAL RELEVANCE OF BIOBANKS	12
SCIENTIFIC AND COMMERCIAL ... (CONTINUED).....	13
<i>TABLE 1 CUMULATIVE NUMBER OF DNA SAMPLES BANKED IN POPULATION-BASED STUDIES*, 1970–2009 (RECRUITMENT START DATE)</i>	 14
<i>TABLE 2 VALUE OF DNA SAMPLES STORED, THROUGH 2015 (\$ MILLIONS)</i>	 14
<i>TABLE 3 NIH-SPONSORED CLINICAL TRIALS CONDUCTING GENE EXPRESSION PROFILING, 2000–2008 (NO.)</i>	 15
MODERN BIOBANKS – PUBLIC SECTOR	15
POPULATION-BASED BIOBANKS.....	15
DISEASE-BASED BIOBANKS	16
BIOBANKING COSTS	17
DRIVERS OF BIOBANKS EXPANSION	18
BARRIERS TO BIOBANKS EXPANSION.....	18
BIOBANKING TRENDS AND FORECAST.....	19
FORECAST FOR BIOBANK INVOLVEMENT IN FUTURE BIOMEDICAL DISCOVERIES.....	 20
FORECAST FOR BIOBANK ... (CONTINUED).....	21
FORECAST FOR BIOBANK ... (CONTINUED).....	22
 CHAPTER FOUR: OVERVIEW OF BIOBANK APPLICATIONS.....	 23

TYPES OF BIOBANK APPLICATIONS	23
TABLE 4 GLOBAL BIOBANKING MARKET BY APPLICATION, THROUGH 2015 (\$ MILLIONS).....	23
BIOMARKERS.....	24
TABLE 5 SELECTED U.S. CANCER BIOBANKS	24
TABLE 6 GLOBAL MARKET FORECAST OF BIOMARKERS IN LATE- STAGE CLINICAL USE BY THERAPEUTIC AREA, THROUGH 2015 (\$ MILLIONS).....	25
OPPORTUNITIES IN CANCER.....	25
TABLE 7 APPLICATIONS OF BIOMARKERS FOR CANCER TREATMENTS	26
OPPORTUNITIES IN CANCER (CONTINUED).....	27
TABLE 8 REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL USE: ONCOLOGY	28
OPPORTUNITIES IN CARDIOVASCULAR DISEASE	29
TABLE 9 REPRESENTATIVE BIOMARKERS IN U.S. CLINICAL USE: CARDIOVASCULAR	30
OPPORTUNITIES IN NEUROLOGICAL DISEASES	30
BRAIN AND CENTRAL NERVOUS SYSTEM DISORDERS	30
Depression.....	30
Major Depressive Disorder.....	31
Adult Attention-Deficit/Hyperactivity Disorder.....	31
Schizophrenia	32
TABLE 10 REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL USE: CNS DISEASE	32
Alzheimer's Disease.....	33
OPPORTUNITIES IN IMMUNOLOGY.....	33
AUTOIMMUNE DISEASES.....	33
TABLE 11 REPRESENTATIVE BIOMARKERS IN GLOBAL CLINICAL USE: IMMUNOLOGY	34
Systemic Lupus Erythematosus	34
OTHER OPPORTUNITIES RESULTING FROM BIOBANKS.....	34
TARGETED THERAPEUTICS	34
DIAGNOSTIC AND PROGNOSTIC TESTS.....	35
Diagnostic Tests.....	36
Prognostic Tests.....	36
DRUG DEVELOPMENT	37
DISEASE ETIOLOGY.....	38
Disease Etiology (Continued).....	39
CHAPTER FIVE: BIOBANKS WORLDWIDE.....	40
OVERVIEW.....	40
FIGURE 1 WORLDWIDE LOCATION OF MAJOR BIOBANKS.....	40
FIGURE 1 (CONTINUED)	41
TABLE 12 TYPES OF BIOBANKS (NO.).....	41

U.S. BIOBANKS	41
TABLE 13 MAJOR NHLBI COHORT STUDIES	42
TABLE 14 EXAMPLES OF MAJOR DISEASE-BASED BIOBANKS	42
EUROPEAN BIOBANKS	43
THE UNITED KINGDOM	43
U.K. Biobank.....	44
Licensed Biobanks in the U.K.....	44
TABLE 15 BIOBANKS LICENSED TO OPERATE IN THE U.K. BY TYPE OF OWNERSHIP, 2008 (NO.).....	45
TABLE 16 FUNDING SOURCES FOR BIOBANKS LICENSED IN THE U.K. BY TYPE, 2009/2010 (%).....	45
BBMRI	46
TABLE 17 COMPOSITE FUNDING METHODS FOR BIOBANKS IN BBMRI COUNTRIES BY SOURCE, 2010 (%).....	47
TABLE 18 JOINT RESEARCH CENTRE SURVEY OF BIOBANKS IN EU COUNTRIES, 2010	48
TABLE 19 EUROPEAN BIOBANKS BY TYPE OF OWNERSHIP, 2010 (%).....	48
TABLE 20 ACCESS TO THE EUROPEAN BIOBANK, 2010 (%).....	49
BIOBANKS IN NORTHERN EUROPE.....	49
Biobanks in Nordic Countries	50
Biobanks in Baltic Countries	51
INTERNATIONAL BIOBANKS IN OTHER PARTS OF THE WORLD.....	52
CANADIAN PARTNERSHIP FOR TOMORROW PROJECT.....	52
FAR EAST BIOBANKS	52
China Biobank	53
CHAPTER SIX: DISEASE-BASED BIOBANKS.....	54
DISEASE-BASED BIOBANKS	54
GROWTH IN DISEASE-BASED BIOBANKS.....	55
TABLE 21 U.S. GROWTH IN DISEASE-BASED BIOBANKS BY THERAPY, 1995–2008 (CUMULATIVE NO. OF BIOBANKS).....	55
CANCER BIOBANKS	56
BIOBANKS FOR OTHER DISEASES	57
Biobanks for Other Diseases (Continued)	58
HEALTHY SAMPLE BIOBANKS.....	59
COLLABORATIVE NETWORKS	60
ONCORE U.K.....	61
INTERNATIONAL GENOMICS CONSORTIUM	61
CANCER GENOME ATLAS.....	62
SEGMENT FORECAST	62
SEGMENT FORECAST (CONTINUED)	63
CHAPTER SEVEN: POPULATION-BASED BIOBANKS	64
INTRODUCTION	64

TYPES OF POPULATION BIOBANKS	65
COHORT STUDIES	65
<i>TABLE 22 SELECTED POPULATION-BASED COHORT BIOBANKS</i>	66
FOUNDER POPULATION BIOBANKS	67
<i>TABLE 23 FOUNDER POPULATION-BASED BIOBANKS</i>	68
DECODE GENETICS	68
CARTAGENE	69
GENIZON BIOSCIENCES	69
JURILAB	70
NATIONAL POPULATION BIOBANKS	70
U.K. BIOBANK	70
U.K. Biobank (Continued)	71
LIFEGENE	72
ESTONIAN BIOBANK	72
LATVIAN BIOBANK	73
CANADIAN PARTNERSHIP FOR TOMORROW PROJECT	73
OTHER NATIONAL BIOBANKS	73
Other National Biobanks (Continued)	74
CHAPTER EIGHT: PRIVATE FOR-PROFIT BIOBANKING COMPANIES	75
CONTRACT BIOBANKING AND SERVICE PROVIDERS	75
CONTRACT BIOBANKING AND SERVICE ... (CONTINUED)	76
BIOMARKER DISCOVERY COMPANIES	77
PHARMACEUTICAL COLLECTIONS	78
RESEARCH COLLABORATIONS	78
CLINICAL TRIALS	79
CLINICAL TRIALS (CONTINUED)	80
CHAPTER NINE: THE LIMITATIONS OF BIOBANKS	81
THE LIMITATIONS OF BIOBANKS	81
SAMPLE VARIABILITY	82
SAMPLE QUALITY	83
EFFORTS TO INCREASE HARMONIZATION	84
EFFORTS TO INCREASE HARMONIZATION (CONTINUED)	85
INITIATIVES TO IMPROVE BIOBANKS	86
INITIATIVES TO IMPROVE BIOBANKS (CONTINUED)	87
CHAPTER TEN: REGULATORY DYNAMICS, INTELLECTUAL PROPERTY, ETHICAL CONSIDERATIONS	88
INTRODUCTION	88
ROLE OF THE FOOD AND DRUG ADMINISTRATION	88
CURRENT REGULATORY FRAMEWORK	89
INFORMED CONSENT	90
INFORMED CONSENT (CONTINUED)	91
WITHDRAWAL AND OWNERSHIP	92

CONFIDENTIALITY.....	93
COMMERCIALIZATION	94
FDA GUIDELINES FOR BIOMARKER APPLICATIONS	95
<i>TABLE 24 FDA GUIDELINES FOR BIOMARKER APPLICATIONS</i>	<i>95</i>
<i>TABLE 24 (CONTINUED).....</i>	<i>96</i>
EUROPEAN MEDICINES AGENCY	96
REGULATORY IMPACT ON DRUG SAFETY	97
INTELLECTUAL PROPERTY AND COMPETITIVE POSITIONING	97
APPROVED PATENT ANALYSIS.....	97
<i>TABLE 25 ANNUAL PATENTS FILED AND APPROVED WITH</i>	
<i>BIOMARKER CLAIMS SINCE 2005 IN U.S., EUROPE, JAPAN,</i>	
<i>THROUGH 2015.....</i>	<i>98</i>
COMPETITIVE LANDSCAPE	98
LATE-STAGE CLINICAL TRIALS: COMPETITIVE	
POSITIONING.....	99
<i>TABLE 26 GLOBAL MARKET FOR CLINICAL STAGE BIOMARKERS</i>	
<i>BY SERVICES AND PRODUCTS, THROUGH 2015 (\$ MILLIONS)</i>	<i>99</i>
<i>TABLE 27 SUMMARY OF RECENT AGREEMENTS IN BIOMARKER</i>	
<i>DELIVERY.....</i>	<i>100</i>
<i>TABLE 28 REPRESENTATIVE LIST OF APPROVED BIOMARKER</i>	
<i>PATENTS IN U.S., EUROPE, JAPAN.....</i>	<i>101</i>
<i>TABLE 28 (CONTINUED).....</i>	<i>102</i>
ETHICAL CONSIDERATIONS	102
SUMMARY	102
REGULATORY IMPLICATIONS	103
 CHAPTER ELEVEN: BIOBANKING MARKETS FORECAST BY	
SEGMENT AND GEOGRAPHY.....	104
<i>TABLE 29 FORECAST GROWTH FOR BIOBANK-RELATED MARKET,</i>	
<i>THROUGH 2015 (\$ MILLIONS).....</i>	<i>104</i>
<i>TABLE 30 GROWTH IN GLOBAL BIOBANKS BY GEOGRAPHIC</i>	
<i>REGION, THROUGH 2015 (\$ MILLIONS)</i>	<i>105</i>
 CHAPTER TWELVE: DETAILED DESCRIPTIONS OF BIOMARKER	
APPLICATIONS.....	106
COLORECTAL CANCER.....	106
PREDICTIVE TESTS	106
Cetuximab.....	106
Panitumumab	107
Panitumumab	108
Elesclomol	109
Herceptin	109
ADDITIONAL PREDICTIVE TESTS	109
<i>TABLE 31 CURRENT ACTIVE BIOMARKER TRIALS ONGOING:</i>	
<i>ONCOLOGY.....</i>	<i>110</i>

<i>TABLE 31 (CONTINUED)</i>	111
<i>TABLE 31 (CONTINUED)</i>	112
<i>TABLE 31 (CONTINUED)</i>	113
<i>TABLE 31 (CONTINUED)</i>	114
BREAST CANCER.....	115
PROGNOSTIC TESTS.....	115
MammaPrint.....	116
<i>TABLE 32 REPRESENTATIVE ACTIVE BIOMARKER TRIALS</i>	
<i>ONGOING: BREAST CANCER</i>	117
<i>TABLE 32 (CONTINUED)</i>	118
<i>TABLE 32 (CONTINUED)</i>	119
Oncotype DX.....	120
TEST ADOPTION.....	121
Test Adoption (Continued).....	122
OTHER PROGNOSTIC TESTS.....	123
THEROS H/I.....	123
Mammostrat.....	123
Breast Cancer Gene Expression Prognosis Profile.....	124
Insight Dx Breast Cancer Profile.....	124
MapQuant Genomic Grade Index.....	125
PREDICTIVE TESTS.....	125
HORMONAL THERAPIES.....	126
TAXANES/ANTHRACYCLINES.....	126
TRIPLE NEGATIVE BREAST CANCER.....	127
OTHER NOVEL BIOMARKERS.....	128
LUNG CANCER.....	128
INTRODUCTION.....	128
PREDICTIVE TESTS.....	128
<i>TABLE 33 REPRESENTATIVE ACTIVE BIOMARKER TRIALS</i>	
<i>ONGOING: LUNG CANCER</i>	129
<i>TABLE 33 (CONTINUED)</i>	130
<i>TABLE 33 (CONTINUED)</i>	131
Gefitinib.....	131
Erlotinib.....	132
OTHER PREDICTIVE TESTS.....	133
NOVEL THERAPIES.....	134
PROSTATE CANCER.....	135
PROSTATE TESTS.....	135
Prostate Px.....	135
Insight Dx Prostate Profile.....	136
Prostate Cancer Prognostic Test.....	136
ProstaCheck.....	136
NADiA ProsVue.....	136
ANDROGEN RECEPTOR.....	137

OVARIAN CANCER	137
MALIGNANT MELANOMA	138
TABLE 34 REPRESENTATIVE ACTIVE BIOMARKER TRIALS	
ONGOING: MALIGNANT MELANOMA	139
TABLE 34 (CONTINUED).....	140
TABLE 34 (CONTINUED).....	141
CARDIOVASCULAR	142
CARDIOVASCULAR (CONTINUED).....	143
TABLE 35 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:	
CARDIOVASCULAR	144
CENTRAL NERVOUS SYSTEM	144
CENTRAL NERVOUS SYSTEM (CONTINUED)	145
TABLE 36 REPRESENTATIVE BIOMARKERS IN CLINICAL USE: CNS	
DISEASE.....	146
TABLE 36 (CONTINUED).....	147
TABLE 36 (CONTINUED).....	148
TABLE 37 BIOMARKERS/TESTS FOR OTHER NEUROLOGICAL	
DISEASES	148
TABLE 37 (CONTINUED).....	149
IMMUNOLOGY-AUTOIMMUNE DISEASES	150
TABLE 38 REPRESENTATIVE BIOMARKERS IN CLINICAL USE:	
IMMUNOLOGY	150
IMMUNOLOGY	150
BENLYSTA: HUMAN GENOME SCIENCES.....	150
EXPEDITION AND IDENTITY ALZHEIMER'S TRIAL: ELI	
LILLY	151
CHAPTER THIRTEEN: COMPANY PROFILES	152
ABBOTT LABORATORIES, INC.....	152
COMPANY OVERVIEW	152
PRODUCTS AND SERVICES	152
TABLE 39 ABBOTT REPRESENTATIVE CLINICAL TRIALS	
INVOLVING BIOMARKERS	153
COMPANY STRATEGY.....	153
AFFYMETRIX, INC.....	154
COMPANY OVERVIEW	154
PRODUCTS AND SERVICES	154
COMPANY STRATEGY.....	154
ASTERAND, PLC	155
COMPANY OVERVIEW	155
PRODUCTS AND SERVICES	156
TABLE 40 ASTERAND'S BIOBANK-RELATED PRODUCTS	156
COMPANY STRATEGY.....	156
ASTRAZENECA, LTD.	156
COMPANY OVERVIEW	156

PRODUCTS AND SERVICES.....	157
<i>TABLE 41 ASTRAZENECA’S REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS</i>	157
COMPANY STRATEGY.....	157
BAYER SCHERING PHARMA AG.....	158
COMPANY OVERVIEW.....	158
PRODUCTS AND SERVICES.....	158
COMPANY STRATEGY.....	158
<i>TABLE 42 BAYER SCHERING PHARMA CLINICAL TRIAL ON BAY94-</i>	
<i>9172</i>	159
BIOCHAIN-GENOMICS	160
COMPANY OVERVIEW.....	160
PRODUCTS AND SERVICES.....	160
<i>TABLE 43 BIOCHAIN’S BIOBANK-RELATED PRODUCTS.....</i>	160
COMPANY STRATEGY.....	161
BIOSTORAGE TECHNOLOGIES, INC.	161
COMPANY OVERVIEW.....	161
PRODUCTS AND SERVICES.....	161
<i>TABLE 44 BIOSTORAGE’S BIOBANK-RELATED PRODUCTS.....</i>	161
COMPANY STRATEGY.....	162
BOEHRINGER INGELHEIM GMBH	162
COMPANY OVERVIEW.....	162
PRODUCTS AND SERVICES.....	162
COMPANY STRATEGY.....	162
BRISTOL-MYERS SQUIBB CO.....	163
COMPANY OVERVIEW.....	163
PRODUCTS AND SERVICES.....	163
<i>TABLE 45 BRISTOL-MYERS SQUIBB’S REPRESENTATIVE</i>	
<i>CLINICAL TRIALS INVOLVING BIOMARKERS</i>	164
COMPANY STRATEGY.....	164
DAIICHI SANKYO CO., LTD.	164
COMPANY OVERVIEW.....	165
PRODUCTS AND SERVICES.....	165
COMPANY STRATEGY.....	165
ELI LILLY AND CO.	166
COMPANY OVERVIEW.....	166
PRODUCT AND SERVICES	166
<i>TABLE 46 ELI LILLY’S REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS</i>	167
COMPANY STRATEGY.....	167
EXIQON LIFE SCIENCES	168
COMPANY OVERVIEW.....	168
PRODUCTS AND SERVICES.....	168
<i>TABLE 47 EXIQON’S BIOBANK-RELATED PRODUCTS.....</i>	168

COMPANY OVERVIEW.....	168
GENTRIS CORP.	169
COMPANY OVERVIEW.....	169
PRODUCTS AND SERVICES.....	169
<i>TABLE 48 GENTRIS' BIOBANK-RELATED PRODUCTS.....</i>	<i>169</i>
COMPANY STRATEGY.....	169
GLAXOSMITHKLINE.....	169
COMPANY OVERVIEW.....	170
PRODUCTS AND SERVICES.....	170
<i>TABLE 49 GLAXOSMITHKLINE'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS.....</i>	<i>170</i>
COMPANY STRATEGY.....	170
JOHNSON & JOHNSON, LTD.....	171
COMPANY OVERVIEW.....	171
PRODUCTS AND SERVICES.....	172
COMPANY STRATEGY.....	172
MILLENIU PHARMACEUTICALS.....	172
COMPANY OVERVIEW.....	173
PRODUCTS AND SERVICES.....	173
<i>TABLE 50 MILLENNIUM'S BIOBANK-RELATED PRODUCTS.....</i>	<i>173</i>
COMPANY STRATEGY.....	173
MERCK & CO.	173
COMPANY OVERVIEW.....	173
PRODUCTS AND SERVICES.....	174
<i>TABLE 51 MERCK'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS.....</i>	<i>174</i>
COMPANY STRATEGY.....	174
NOVARTIS AG.....	175
COMPANY OVERVIEW.....	175
PRODUCTS AND SERVICES.....	176
<i>TABLE 52 NOVARTIS' REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS.....</i>	<i>176</i>
COMPANY STRATEGY.....	176
PFIZER, INC.....	177
COMPANY OVERVIEW.....	177
PRODUCTS AND SERVICES.....	177
COMPANY STRATEGY.....	178
ROCHE, LTD.	178
COMPANY OVERVIEW.....	179
PRODUCTS AND SERVICES.....	179
<i>TABLE 54 ROCHE'S REPRESENTATIVE CLINICAL TRIALS INVOLVING BIOMARKERS.....</i>	<i>179</i>
COMPANY STRATEGY.....	179
SANOFI-AVENTIS.....	180

COMPANY OVERVIEW.....	180
PRODUCTS AND SERVICES.....	180
<i>TABLE 55 SANOFI-AVENTIS' REPRESENTATIVE CLINICAL TRIALS</i>	
<i>INVOLVING BIOMARKERS</i>	181
COMPANY STRATEGY.....	182
SCIPAC.....	182
COMPANY OVERVIEW.....	183
PRODUCTS AND SERVICES.....	183
<i>TABLE 56 SCIPAC'S BIOBANK-RELATED PRODUCTS</i>	183
COMPANY STRATEGY.....	183
TAKEDA PHARMACEUTICALS, LTD.	183
COMPANY OVERVIEW.....	184
PRODUCTS AND SERVICES.....	184
COMPANY STRATEGY.....	184
TEVA PHARMACEUTICAL INDUSTRIES, LTD.	185
COMPANY OVERVIEW.....	185
PRODUCTS AND SERVICES.....	186
COMPANY STRATEGY.....	187